BioSpace News Archive

Dr. F. Victor Rueckl wins bronze level award for Best Dermatologist

Repro Med Systems, Inc. dba RMS Medical Products (OTCQX: REPR) (“RMS Medical” or “the Company”) today announced that its common stock has been approved for listing and is expected to begin trading on the NASDAQ Capital Market on October 17, 2019 under the current symbol “REPR”.

New kit shown to achieve over 90% correlation rate between biopsied embryos and testing spent culture media

Hologic, Inc. (Nasdaq: HOLX), is the maker of the Genius™ 3D Mammography™ exam, the only mammogram clinically proven to detect 20 to 65 percent more invasive breast cancers compared to 2D mammography alone.

Cigna is expanding in Colorado, offering for the first time Medicare Advantage (MA) plans in the Denver and Boulder areas. These plans will first be available to Medicare eligible customers during Medicare’s Annual Election Period (AEP), which begins Oct. 15 and continues through Dec. 7, for plans that take effect Jan. 1, 2020.

ELLKAY’s VP of Marketing and Strategy Brings Passion for Collaboration and Innovation to the College of Healthcare Information Management Executives Foundation Board and Board of Trustees.

NAFLD is a substantial cause of liver-related morbidity in people living with HIV and is a precursor of Non-alcoholic steatohepatitis

Technavio has been monitoring the global HIV therapeutics market since 2016 and the market is poised to grow by USD 2.44 billion during 2019-2023, progressing at a CAGR of almost 2% during the forecast period.

VIDA Diagnostics, Inc. (“VIDA”), the leader in AI-powered lung imaging analysis, announced a distribution agreement with TeraRecon, Inc., a leader in advanced visualization, artificial intelligence, image viewing, and post-processing

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, today announced positive additional results from an ongoing Phase I/IIa study of its lead product candidate, OpRegen®, a retinal pigment epithelium cell transplant therapy currently in development for the treatment of dry age-related macular degeneration (dry AMD)